LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)
Status:
Terminated
Trial end date:
2018-09-24
Target enrollment:
Participant gender:
Summary
The purpose of the study was to evaluate whether LYS228 can be developed for the treatment of
complicated intra-abdominal infections.
It was planned that LYS228 exposure across patients with varying renal function would be
evaluated during the study to confirm that LYS228 concentrations are predicted to be adequate
to treat the patient population. It was planned that the PK exposure of the initial 8
patients would be analyzed.
PK analysis was not conducted as per protocol the first analysis required 8 patients.